Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Robert Millham"'
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 7. Results of the pharmacodynamic analysis of tumor-associated biomarkers following treatment with PF-05212384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b46c240c8b64ebf0330fc492627ae09
https://doi.org/10.1158/1078-0432.22456157
https://doi.org/10.1158/1078-0432.22456157
Autor:
Manuel Hidalgo, Alex A. Adjei, Michael J. Wick, Nagdeep Giri, Robert Millham, Joseph O'Connell, Diana Gernhardt, Anthony W. Tolcher, Rastilav Bahleda, Tao Wang, Wen Wee Ma, Jean-Charles Soria, Emiliano Calvo
Supplementary Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc7b28485d54daef1abfee78646300c
https://doi.org/10.1158/1078-0432.22458201.v1
https://doi.org/10.1158/1078-0432.22458201.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 6. Changes observed in metabolic biomarker levels following treatment with PF-05212384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517bb1bc2edce5bc332ca3b1b3d79d69
https://doi.org/10.1158/1078-0432.22456160.v1
https://doi.org/10.1158/1078-0432.22456160.v1
Autor:
Jan H.M. Schellens, S. Gail Eckhardt, Ian Taylor, Robert Millham, Stephen Letrent, Jane Liang, Steven Wong, Feng Guo, Edward B. Garon, Jeffrey A. Engelman, Carolyn D. Britten, D. Ross Camidge, David S. Boss, Pasi A. Jänne
Purpose: PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This first-in-human study investigated the safety, tolerability, pharmacokinetics, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8971b92fd2f2d222a6fddd608208c64a
https://doi.org/10.1158/1078-0432.c.6520385
https://doi.org/10.1158/1078-0432.c.6520385
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 1. Additional study results on treatment-related adverse events at dose levels below the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126227ee45601a14d10657779d0ada10
https://doi.org/10.1158/1078-0432.22456175.v1
https://doi.org/10.1158/1078-0432.22456175.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 3. Cycle 1 results of the pharmacokinetic analysis of PF-05212384 administered at the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f79cf89011c4a0210cc955c3f4cde0
https://doi.org/10.1158/1078-0432.22456169.v1
https://doi.org/10.1158/1078-0432.22456169.v1
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Supplemental Table 2. Additional study results on treatment-related adverse events at dose levels above the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c79d3f495a242cc7fefed02ad412ef
https://doi.org/10.1158/1078-0432.22456172.v1
https://doi.org/10.1158/1078-0432.22456172.v1
Autor:
Jan H.M. Schellens, S. Gail Eckhardt, Ian Taylor, Robert Millham, Stephen Letrent, Jane Liang, Steven Wong, Feng Guo, Edward B. Garon, Jeffrey A. Engelman, Carolyn D. Britten, D. Ross Camidge, David S. Boss, Pasi A. Jänne
Supplementary Figures S1-S5; Supplementary Tables S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bca1ff9166c4b5a5bd0fb2e4fa6ce0f
https://doi.org/10.1158/1078-0432.22445072
https://doi.org/10.1158/1078-0432.22445072
Autor:
Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors.Experimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::003f2b2e15a90921cbad4234cbd0e0ae
https://doi.org/10.1158/1078-0432.c.6523223.v1
https://doi.org/10.1158/1078-0432.c.6523223.v1
Autor:
Manuel Hidalgo, Alex A. Adjei, Michael J. Wick, Nagdeep Giri, Robert Millham, Joseph O'Connell, Diana Gernhardt, Anthony W. Tolcher, Rastilav Bahleda, Tao Wang, Wen Wee Ma, Jean-Charles Soria, Emiliano Calvo
Supplementary material Supplementary Table 1. Customized primer panel for Sequenom MassARRAY® somatic mutation profiling of DNA from models of adenoid cystic carcinoma. Supplementary Figure 1. Apparent oral clearance (CL/F) of dacomitinib 10 mg (D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345f07296fe6a92536b2158828a7f344
https://doi.org/10.1158/1078-0432.22458204.v1
https://doi.org/10.1158/1078-0432.22458204.v1